Critères d'inclusion : - Histologically-confirmed cancer of unknown primary site (CUP)(non-specific subset) according to criteria from the European Society for Medical Oncology, version 1 (ESMO v1)
- Each patient must provide a blood sample for genomic profiling
- No prior lines of systemic therapy for the treatment of CUP
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Candidate for platinum-based doublet chemotherapy (according to the reference information for the intended doublet therapy)
- At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors, version 1.1 (RECIST v1.1)
- Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue sample that is sufficient for generation of a comprehensive genomic profile at a central reference pathology laboratory
Critères de non-inclusion : - Squamous cell CUP
- History or known presence of leptomeningeal disease
- Known human immunodeficiency virus (HIV) infection
-Significant cardiovascular disease
- Prior allogeneic stem cell or solid organ transplantation
- Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or for up to 24 months after the last dose of study treatment